Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Date
On July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). Read more. 
Share information with your patients to help protect them from surprise billing. As of January 1, 2022, your patients have billing protections when they receive emergency care, non-emergency care from out-of-network providers at in-network facilities and air ambulance services from out-of-network providers. There are four new No Surprises fact sheets:
On June 24, 2022, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. It is not indicated for the treatment of patients with primary central nervous system lymphoma.
The Centers for Medicare and Medicaid Services (CMS) is hosting a Home Health, Hospice & DME Open Door Forum on June 29, 2022, from 2:00 – 3:00 PM ET. The forum will provide announcements and updates on the 2023 HH PPS Proposed Rule Update and June 2022 Hospice.
On May 25, 2022, the Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. View full prescribing information for Tibsovo.  
Biosimilars are safe and effective for treating many illnesses, including chronic skin diseases, inflammatory bowel diseases, arthritis, kidney conditions, diabetes, and cancer. The Food and Drug Administration (FDA) provides help resources including:
On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Read more.   
Over 7% of the U.S. population are Asian Americans, Native Hawaiians, and other Pacific Islanders. Uninsured rates vary among the different ethnicities in this group. The Centers for Medicare and Medicaid Services (CMS) is committed to policy and equity initiatives that help these communities find and use health care. During National Asian American, Native Hawaiian, and Pacific Islander Heritage Month, learn about the health needs of this population and find out how to reduce health disparities.